secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0001193125-24-032780
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs and Ono Pharma collaborate on fusion proteins; upfront $9M, milestones up to $217.5M
--------------------------------------------------------------------------------

- Upfront payment plus research milestones total up to $9M; Ono reimburses all research costs.
- Exclusive option for Ono to license compounds after research; exercise triggers up to $217.5M in development, regulatory, and commercial milestones.
- Tiered royalties on global net sales: mid-single digit to low double digit percentages per product/country for 10 years.
- Parties cannot commercialize products with same mechanism of action globally during the agreement term.
- Ono can terminate on 90 days' notice; Shattuck can terminate if Ono abandons development after option exercise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000119312524032780/0001193125-24-032780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000119312524032780/d780650d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-032780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer